New drug DD01 shows promise for fatty liver in early trial

NCT ID NCT06410924

Completed Disease control Sponsor: Neuraly, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tested a drug called DD01 in 67 overweight or obese adults with a type of fatty liver disease (MASLD/MASH). The goal was to see if DD01 could safely reduce liver fat by at least 30% over 48 weeks compared to a placebo. The study is completed, and results will show whether DD01 is a potential treatment for this common liver condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DD01 (a dual GLP-1 and glucagon receptor agonist)
What this could lead to: If successful, DD01 could offer a new treatment option to reduce liver fat and improve liver health in people with MASLD/MASH.
What could go wrong: This is a small Phase 2 trial with only 67 participants, so results may not apply to everyone. The drug may cause side effects or fail to show clear benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NAFLD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fatty liver disease liver disorder metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NAFLD NASH

Contacts and locations

Locations

Summit Research Site

Maitland, Florida, 92751, United States
Summit Research Site

Monroe, Louisiana, 71201, United States
Summit Research Site

West Monroe, Louisiana, 71291, United States
Summit Research Site

Kansas City, Missouri, 64131, United States
Summit Research Site

Austin, Texas, 78757, United States
Summit Research Site

Bellaire, Texas, 77401, United States
Summit Research Site

Brownsville, Texas, 78520, United States
Summit Research Site

Corpus Christi, Texas, 78404, United States
Summit Research Site

Edinburg, Texas, 78539, United States
Summit Research Site

Georgetown, Texas, 78626, United States
Summit Research Site

San Antonio, Texas, 78222, United States
Summit Research Site

San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.